Literature DB >> 8040430

Quantitative MR analysis of glucocorticoid effects on peritumoral edema associated with intracranial meningiomas and metastases.

C Andersen1, J Astrup, C Gyldensted.   

Abstract

OBJECTIVE: The purpose of our study was to quantify peritumoral brain edema (PTE) in vivo using NMR relaxation time imaging, as the longitudinal relaxation time T1 is proportional to tissue water content, and to use the method for monitoring the effects of glucocorticoids (GCCs) on PTE in brain tumor patients as a function of time.
MATERIALS AND METHODS: Relaxation time imaging (T1 maps) was done on a 1.5 T MR scanner on 23 brain tumor patients [13 cerebral metastases (METs), 10 intracranial meningiomas (MMs), and 9 benign and 1 anaplastic MM] before, and 1, 3, and 7 days after initiation of GCC treatment (dexamethasone 0.26-0.64 mg/kg bw). In addition, 7 patients were studied for 14-63 days of treatment. Imaging analysis included mean T1 of the edema area as a function of time, and an image histogram evaluation technique, which measures 50% of the edema area, where T1 is highest (corresponding to the highest water content of the area), termed the "super-edema." Using a conversion equation, mean T1 in the edema area was recalculated into a percent of tissue water content.
RESULTS: After 7 days of GCC treatment total edema area was reduced by 10.3% in the MET patients. The average reduction in mean T1 was 4.6% after 24 h of treatment and 13.5% after 7 days. Expressed in terms of percent tissue water content, the average edema resorption rate in the MET patients was 0.4 +/- 0.1% H2O/day (p < 0.02). Super-edema area was reduced by 64% after 7 days (p < 0.0001). None of the benign MMs responded to GCC treatment, either in edema size or in mean T1, unlike the anaplastic type, in which there was a response comparable to that in the MET patients. The effect of GCCs in up to 63 days of treatment is demonstrated. It is shown that after 40-63 days of GCC treatment, PTE water content is close to the upper normal range for white matter.
CONCLUSION: PTE is heterogeneous in terms of the spatial distribution of T1 and, thereby, water content. GCCs reduce T1 in PTE around cerebral metastases significantly after a few days of treatment, possibly through a mechanism that reduces edema production below the level of edema resorption. PTE surrounding benign MM was not affected by GCC treatment, contrary to one anaplastic MM, which leads to the speculation that malignant tumors may produce substances that are affected by GCCs and are prerequisites for a GCC effect. Significant reductions in the highest T1 area (super-edema area) were observed after 24 h of treatment. The anti-edema effect of GCC may last at least 63 days. A lower dose-dependent threshold for the effect seems to exist. The possible mechanisms of actions of the GCCs on PTE are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040430     DOI: 10.1097/00004728-199407000-00001

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  7 in total

Review 1.  Metastatic disease of the brain: parenchyma.

Authors:  Gaida Krumina
Journal:  Eur Radiol       Date:  2005-02-05       Impact factor: 5.315

2.  T1 and ADC histogram parameters may be an in vivo biomarker for predicting the grade, subtype, and proliferative activity of meningioma.

Authors:  Tiexin Cao; Rifeng Jiang; Lingmin Zheng; Rufei Zhang; Xiaodan Chen; Zongmeng Wang; Peirong Jiang; Yilin Chen; Tianjin Zhong; Hu Chen; PuYeh Wu; Yunjing Xue; Lin Lin
Journal:  Eur Radiol       Date:  2022-08-12       Impact factor: 7.034

3.  Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging.

Authors:  Sosuke Minamikawa; Kinuko Kono; Keiko Nakayama; Hiroyuki Yokote; Takahiko Tashiro; Akimasa Nishio; Mitsuhiro Hara; Yuichi Inoue
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

Review 4.  ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.

Authors:  Simon Shek-Man Lo; Elizabeth M Gore; Jeffrey D Bradley; John M Buatti; Isabelle Germano; A Paiman Ghafoori; Mark A Henderson; Gregory J A Murad; Roy A Patchell; Samir H Patel; Jared R Robbins; H Ian Robins; Andrew D Vassil; Franz J Wippold; Michael J Yunes; Gregory M M Videtic
Journal:  J Palliat Med       Date:  2014-06-27       Impact factor: 2.947

5.  Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance.

Authors:  Christian Hoffmann; Luitpold Distel; Stefan Knippen; Thomas Gryc; Manuel Alexander Schmidt; Rainer Fietkau; Florian Putz
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

6.  Efficiency of Dexamethasone for Treatment of Vasogenic Edema in Brain Metastasis Patients: A Radiographic Approach.

Authors:  Tanja Schroeder; Paul Bittrich; Clara Noebel; Jan Felix Kuhne; Julian Schroeder; Gerhard Schoen; Jens Fiehler; Helge C Kniep; Susanne Gellißen
Journal:  Front Oncol       Date:  2019-07-30       Impact factor: 6.244

7.  Radiographic markers of breast cancer brain metastases: relation to clinical characteristics and postoperative outcome.

Authors:  Anna Michel; Thiemo Dinger; Marvin Darkwah Oppong; Laurèl Rauschenbach; Cornelius Deuschl; Yahya Ahmadipour; Daniela Pierscianek; Karsten Wrede; Jörg Hense; Christoph Pöttgen; Antonella Iannaccone; Rainer Kimmig; Ulrich Sure; Ramazan Jabbarli
Journal:  Acta Neurochir (Wien)       Date:  2021-10-22       Impact factor: 2.216

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.